
Coegin Pharma - Outcome of TO3 warrants

Redeye provides a short research update following the outcome of the TO3 warrants recently published by Coegin Pharma. We are encouraged by the high subscription rate and the much-needed capital injection. Having adjusted for the outcome of the warrants, we revise our fair value range with an adjusted base case of SEK9 (10).

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Coegin Pharma - Outcome of TO3 warrants](#)